Characteristics and clinical significance of T lymphocyte subsets in peripheral blood during immune tolerance period of chronic HBV infection

doi:10.19871/j.cnki.xfcrbzz.2022.04.002

Abstract

Abstract: Objective To study the characteristics of peripheral blood T lymphocyte subsets in patients with chronic HBV infection during immune tolerance period, and to evaluate their role in immune tolerance status, the significance of antiviral timing during immune tolerance period, and the role in HBV infection. Method A total of 79 patients (immune tolerance group), 152 non immune tolerance patients (non immune tolerance group) and 44 healthy volunteers (healthy control group) in the immune tolerance period of chronic HBV infection hospitalized in the Infection Department of the First Affiliated Hospital of Nanchang University from December 2018 to December 2020. Basic data and clinical indicators were collected, and the diagnostic efficacy of T lymphocyte subsets in evaluating immune status was observed. At the same time, 55 patients with chronic HBV infection in immune tolerance stage were followed up to observe the diagnostic efficacy of T lymphocyte subsets for breaking immune tolerance and the difference of T lymphocyte subsets in peripheral blood of patients with and without breaking immune tolerance Result ①The absolute values of CD3+, CD4+, CD8+T lymphocytes and the ratio of CD4+/CD8+T lymphocytes in immune tolerance group and non-immune tolerance group after HBV infection were significantly lower than those in healthy group (P<0.05). The absolute values of CD3+ and CD4+T lymphocytes, the proportion of CD4+T lymphocytes and the ratio of CD4+/CD8+T lymphocytes in immune tolerance group were lower than those in non-immune tolerance group, and the differences were statistically significant (P<0.05). ②The area under the curve of the absolute value of CD4+T lymphocytes, the proportion of CD4+T lymphocytes and the ratio of CD4+/CD8T lymphocytes in evaluating immune status were 0.774, 0.827 and 0.721, respectively. ③The area under the curve of the number of CD3+, CD4+, CD8+T lymphocytes and the ratio of CD4+/CD8+T lymphocytes for breaking immune tolerance were 0.831, 0.892, 0.802, 0.837, respectively. Conclusion ①The decline of cellular immune function and immune disorder are common after HBV infection. ②The absolute number and proportion of CD4+ cells and CD4+/CD8+T ratio have a good effect on the evaluation of immune status in patients with HBV infection. The number of CD3+, CD4+, CD8+T cells and CD4+/CD8+T ratio have a certain reference value for predicting the breaking of immune tolerance status in patients with immune tolerance. Clinically, peripheral blood T lymphocytes can be dynamically detected to assist in evaluating the immune status of patients and the possibility of breaking immune tolerance, so as to understand the immune status of patients and start antiviral therapy in time.

Key words: Hepatitis B virus, Chronic viral hepatitis B, Immune tolerance period, Antiviral, T lymphocyte subsets

Xu Qinglang, Huang Jiansheng, Fu Jiwei, Zhu Ying, Yuan Songsong, Wu Xiaoping. Characteristics and clinical significance of T lymphocyte subsets in peripheral blood during immune tolerance period of chronic HBV infection[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(4): 6-11.

References

[1] WORLD HEALTH ORGANIZATION. Global Hepatitis Report2017[EB/OL]. [2019-11-06]. https:www.who.inthepatitis pubications global-hepatitis-report2017en.
[2] 王贵强, 段钟平, 王福生,等. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1):9-32.
[3] CAREY I, D'ANTIGA L, BANSAL S, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy[J]. J Virol, 2011, 85: 2416-2428.
[4] ANDREANI T, SERFATY L, MOHAND D, et al.Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome[J]. Clin Gastroenterol Hepatol, 2007, 5: 636-641.
[5] MASON WS, GILL US, LITWIN S, et al. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant[J]. Gastroenterology, 2016, 151: 986-998.e4.
[6] 丁霞,廖桂婵,夏牧晔,等. 探讨长期核苷(酸)类药物治疗慢性乙型肝炎患者停药后复发的影响因素[J].新发传染病电子杂志,2019,4(1):52-55.
[7] 孙琳, 毕惠娟, 王健. 慢性乙肝致炎的细胞分子机制[J]. 中国病原生物学杂志, 2010, 5(8):621-626,645.
[8] WONG GL.Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend[J]. Clin Mol Hepatol, 2018, 24(2): 108-113.
[9] 高红艳, 刘娜, 李春霞, 等. 慢性乙型肝炎病毒感染者免疫耐受期的临床特征与肝组织病理学分析[J]. 肝脏, 2018, 23(2):136-139.
[10] 张鸿飞, 朱世殊, 杨晓晋, 等. 小儿乙、丙型肝炎临床与病理研究[J]. 传染病信息, 2006, 19(3):130-131,141.
[11] WANG C. SINGER M, ANDERSON AC.Molecular Dissection of CD8 T-Cell Dysfunction[J]. Trends Immunol, 2017, 38(8): 567-576.
[12] 蓝云翠,刘曦,丁立,等. 611例CHB患者的临床指标与肝脏组织学关系研究[J/CD].新发传染病电子杂志,2017,2(2):72-75.
[13] ZHANG N, BEVAN MJ.CD8(+) T cells:foot soldiers of the immune system[J]. Immunity, 2011, 35(2): 161-168.
[14] MOSMANN TR, CHERWINSKI H, BOND MW, et al.Two types of murine helper T cell clone. I.Definition according to profiles of lymphokine activities and secreted proteins[J]. J Immunol, 1986, 136(7):2348-2357.
[15] FISICARO P, VALDATTA C, MASSARI M, et al.Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B[J]. Gastroenterology, 2010, 138(2):682-693.
[16] TANG TJ, KWEKKEBOOM J, LAMAN JD, et al.The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection[J]. J Viral Hepat, 2003, 10(3): 159-167.